Table 2.
Effects of switching to insulin degludec on glycemic control.
| Baseline | 4 weeks | 12 weeks | P ∗ | |
|---|---|---|---|---|
| Fasting plasma glucose (mg/dL) | 203.2 ± 81.2 | 165.5 ± 82.1 | 206.5 ± 122.4 | 0.91 |
| HbA1c (%) | 8.5 ± 1.4 | 8.6 ± 1.6 | 8.7 ± 1.6 | 0.28 |
| Glycosylated albumin (%) | 24.9 ± 5.0 | 25.3 ± 5.2 | 24.7 ± 3.6 | 0.81 |
| Basal insulin dose (U) | 15.2 ± 7.6 | 13.3 ± 6.8 | 11.6 ± 6.9 | <0.01 |
| Bolus insulin dose (U) | 24.8 ± 11.1 | 24.9 ± 11.1 | 25.6 ± 11.4 | 0.08 |
| Total daily dose (U) | 40.0 ± 17.3 | 38.1 ± 16.6 | 37.9 ± 16.7 | <0.01 |
Data are mean ± SD.
∗Between baseline and 12 weeks after switching to insulin degludec by the Mann-Whitney U test.